Commentary
While some aetiologies can be characterised, a multifactorial disease such as MAFLD requires thorough assessment of comorbidities and severity of concomitant fibrosis to assess a patient’s overall risk.
In this review, L. Hartl et al. (Medical University of Vienna, Austria) summarise the most recent literature on treatment options for MAFLD and NASH and highlight important considerations to tailor therapy to individual patient’s needs in light of their risk profile.
